CXCL5 and cholangiocarcinoma: In CCA, LECs display an “inflamed” phenotype, enabling them to secrete CXCL5, which acts in a paracrine fashion on tumoral cholangiocytes, inducing the neoexpression of CXCR2, the cognate receptor of CXCL5.